Compounds > 9,10-dimethyl-1,2-benzanthracene
Page last updated: 2024-08-17

9,10-dimethyl-1,2-benzanthracene and o-(chloroacetylcarbamoyl)fumagillol

9,10-dimethyl-1,2-benzanthracene has been researched along with o-(chloroacetylcarbamoyl)fumagillol in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Iino, Y1
Gear, RB; Heffelfinger, SC; LaDow, K; Lu, F; Pyle, AL; Schneider, J; Warshawsky, D; Yan, M1

Other Studies

2 other study(ies) available for 9,10-dimethyl-1,2-benzanthracene and o-(chloroacetylcarbamoyl)fumagillol

ArticleYear
Treatment of tamoxifen-refractory breast cancer--approach by animal models.
    Breast cancer (Tokyo, Japan), 2001, Volume: 8, Issue:4

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyclohexanes; Disease Models, Animal; Female; Mammary Neoplasms, Experimental; Mice; Mice, Nude; O-(Chloroacetylcarbamoyl)fumagillol; Picibanil; Prognosis; Rats; Receptors, Estrogen; Risk Assessment; Sesquiterpenes; Tamoxifen; Tegafur; Treatment Failure; Uracil

2001
TNP-470 inhibits 7,12-dimethylbenz[a]anthracene-induced mammary tumor formation when administered before the formation of carcinoma in situ but is not additive with tamoxifen.
    Laboratory investigation; a journal of technical methods and pathology, 2003, Volume: 83, Issue:7

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Carcinogens; Carcinoma in Situ; Carcinoma, Intraductal, Noninfiltrating; Cyclohexanes; Disease Models, Animal; Drug Interactions; Female; Mammary Neoplasms, Experimental; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Precancerous Conditions; Rats; Rats, Sprague-Dawley; Sesquiterpenes; Tamoxifen

2003